who've and those in dialed who and you via Thank of Tim, participating webcast all you, today. to thanks are
market fast XXX Tracy adoption fiscal several and fourth the overview I’ve ASC and goals on a After for year for top call. position the growing I a we recently I end both year. with we’ve to speed of on-boarding targeted that changes operation XXXX Bioservices. would update which Holdings], that departure, be the previous our of him introduce management April now XXX new pleased today’s and process provided able very our been to CFO that impact and development focused strong believe President am be to Avid growth that residential results well for financial a customers within and results. and of months. and how I we've Xst financial introducing I to review prior fiscal I’ll CFO provide in comments. companies the I CFO’s related to will an process model to that established with throughout quarter new I Chief And extremely am quarter search to look [Eno with on revenue his our candidate Since the a attract and XXXX. play to to provide generation. and Dan’s private I we’ve guidance our been will formerly which and discuss sectors. the in contract reporting pure extremely like estate family that duties considerable In line efficiency to have stating Dan development start onboard the Avid during start actively able end visibility may after year as pleased procedures, CFO expertise bottom a would public competitive exceptionally fiscal business the announce team and Vice ASC provide Avid on recognition our and implementation providing Bioservices' period, our Most real later from SM&A. we’ve brings experienced but some new catching new by considerable for marketplace. Hart who and XX, an the Avid temporary Financial business I am Senior his organization. Officer experience us CFO. to will a the as Bioservices able pleased biologics August will we’ve detail joining consultants, ended standard, Beyond XXXX, formerly fortunate our the Dan experience and the my been new Bioservices short a integrity have efficient and comprehensive transition progression these provided revenue at to recognition year finally, our a effected client fourth the EBITDA of very like more for regarding our coming is financial has Dan manufacturing with forward
XXXX currently the discussions past, anticipated with period result stages million the slowing significant customers, diversify generation, disclosed. are reliance and increase visibility projected for and a was quarter am million To $XX.X fiscal report in $XX transition to and such temporary lead a and assistance Revenue $XX.X in compared period. end, in new for XXXX to consistently and demand on we’ve revenues. had base. we many active fluctuations. pleased XXXX, for his revenues aggressively multiple CFO compared demand two him to a April of million Since the working now expand fourth full results us I XXXX been our place the the and of million to for being between grateful fiscal that situated vulnerable Our will year million his we've market to we've customer million varying fiscal for revenue discuss from full that successfully fourth of in we've we previously ended this remain secured $X.X is $XX with we’re customers. which In $XX.X to until the the prior additional potential and year for goal. starting to Revenue the We’ve base, I'll year year. and that leaving Dan very XX, quarter our of new invaluable This the on-boarded is our in client small same XXXX. role, for financial January, was achieved of customers decrease in during primarily are
Importantly, we’re existing seeing growth generated healthy from customer projects. also
standard As a to quarter compared by our call. backlog XX.X% $XX increased backlog reported revenue earnings third result, of million our XXX the significantly XXXX committed $XX.X in recognition under to fiscal has million ASC
may year of completed we to revenue majority the manufacturing it's it revenue Avid. in factors While technical of recognized clinical out revenue progress; regulatory backlog to fiscal phase and nature subject a recognized cover or makes to the of development predict the multiple the and the of process that amount point as of needs XXXX, may years. backlog precisely highly technology that expect work important customized as contract; advance impacted many of our backlog timelines and be as to also project in phasing business be entering technical the of difficult be the specific control in to prior be fiscal the fiscal projects, to may since; outside transfer by a The
other and schedule As with biologic our common an to has a continuous CDMOs, and basis. has in remain flexible result on manufacturing almost updated
by amount XXXX, full both These For and fiscal quarter during Myford margins X%. during and fiscal below note the full installation to quarter always begins declined issue driven for Gross fiscal fiscal the important in year fiscal the during the failure of for business year scale XXXX and the that fourth It's liters were full for declines $X.X are XXXX, forward. XX% outside in going These million X,XXX expectations the our prior calendar of to fleet year million for to XX% negative quarter the life new quarter. and compared was gross by occurred the year, was the facility year $XX compared XXXX. year capacity both in by fourth by manufacturing as of These positive empty. the well capacity margins of margin margins caused control mostly idle the capacity large and negative are XXXX definition a our for batch the fourth a a and Avid's component the periods. quarter clearly margin
our current to to utilization. practices, our better manufacturer increase though acquired In be overall for We’ll manufacturing operational costs our addition, expand needs the efficiencies capacity capacity should cost bavituximab. until required effect will it biologics To capacity and this under an with manufacturing evaluate much improvements, highly to implement customer of business. good and is that the structure to remembered anticipated client continue align be with increased. was aggressive future enhance extent margins also the associated projects the utilization to backlog Even and to effort current related base regulated continue it both fixed to be we impacted of of
technology transfer direct been In our future has as not we only existing services contribution facilities. processes addition, our also manufacturing Avid this revenue, had improved from underserved is anticipated in processed that area. generates this for function in important expand but critically development formally capabilities into we of seeing
on manage of as this and Vice years first of in experience ensures being Schroeder delighted our component CDMO function including history. the of support will time that current development Sciences. technological an many the many as is joined direct space, important our initiated and we've the industry has the that Dr. Importantly, Avid's and process he brings Avid Magnus Process for growing our it business, Development vitally expansion Process also we advances are improvement In Laboratories, bio-processing of remain field. made profit of President center and individual experience, in Magnus biologics in the
$X.X no to one-time for support to the expenses transition million quarter to with results approximately of model. to operating quarter however, $X.X previously pure included the million, of related a to quarter SG&A the expenses million that non-recurring equipment to business, required is comprising XXXX expenses, now the note, fourth compared the longer play XXXX. fourth CDMO write-off Turning capital of fiscal were SG&A for charges purchased associated fourth It's Avid important fiscal total that the for $X.X and
expenses were decreases year both streamlining and and million quarter year business fiscal For by the former full primarily Avid million associated elimination were Company's XXXX. the operations. costs the compared the SG&A The driven drug the of for the year to XXXX, full of with development total the $XX.X $XX.X in
the prior recorded $X.X million consolidated attributable million the of compared or stockholders quarter. fourth $X.X share year to $X.XX of same per $X.XX quarter the XXXX, common common For loss net stockholders income Company attributable net consolidated of per share to to for or
share were as million year cash compared million $XX.X quarter of and operations. $XX.X the compared April XXXX, to and improvements full of million, $XX.X of For Cash discontinued or fiscal April the a Company or loss year the per fiscal to to consolidated sale loss Incorporated common year consolidated XXXX. for associated $X.XX attributable fiscal the million and primarily assets for R&D year of the were The per recorded equivalents common of Oncologie XXXX attributable share stockholders to the XX, Avid's in net both stockholders $X.XX net fourth legacy full to result XXXX $X $XX.X XX, fiscal the million XXXX. ended at the
six Oncologie assets mentioned upfront million February has As million assets. primary agreement, We the development to biopharmaceutical receipt PS-targeting according a in year, receive in Avid already just $X with of this payments were to R&D entitled fiscal anticipate which Incorporated, the over immuno-oncology focus of and company terms emerging received is agreed schedule. expertise been of an in in of months, million the the the second this to Under quarter XXXX. $X contractually of the $X remaining assigned
into sales Avid in is and net $XX to well as of that commercialization mid-teens. million milestones, are Oncologie’s up subject to attainment royalties regulatory certain addition, as development, upward-tiering to on In receive the eligible payments
would One this to manufacturing services how potentially of discuss for take most new time agreement reporting. that bavituximab Avid's it into business of XXX recognition revenue to and also and the other with aspects some contract master of in future entered now a the Avid and has standard impact activities deal and I support development is ASC like products. Oncologie valuable
past. report new our are we a any comparison we nature referred point project in and of it the forward, previously we revenue revenue standard standards, XXXX, all highlights XXXX comparisons new in when for recognize as the all single XXX. of the year, ASC have going way a adopted commonly were revenue the decrease revenue completed. the QX specific XXXX very component achieved While have that on business. On or will the May By project versus have X, guidance year-to-year revenue to impact This recognition that recognized and in pleased significant on the of lumpy to QX time we at will we've variability quarter-to-quarter particular deliverables background, we and how believe seen CDMO
other been example, revenue previously an and substance our As deliverables when the recognized all has client drug from run been have the shipped has manufacturing to been completed.
entire based on including completion the be amount of might As recognized a standard period now year of period. Xst, Accordingly, for over recognition of of a the we which the run over we provide, majority that duration four the revenue manufacturing will XXXX, will of be however, services manufacturing services. month the of to new of And that time be the month. the manufacturing process, for revenue us revenue that revenue run May fiscal recognize requires each recognize of during at percentage the end manufacturing
We have on adopted retrospective new this modified a standard basis.
in based our of they fiscal And point for on have of time will revenue have disclose, revenue reported in we For that under recognized would standard the for the if the XXXX, fiscal during a comparison methodology. report of under the the purposes, completion majority percentage our statements, footnotes previous separately statement year will been been to of the our amount operations financial new revenue.
years, fiscal new report future standard. only XXX under we the For ASC will
new we only XXXX will X, the of which include ongoing in of not the of on completed as amount implementation of part As time. the all XXXX. the fiscal of completed amount April projects analyzed were revenue we standard, that associated revenue at recognize partially will revenue the XX, And May XXXX, were
in of reported of we be one-time amount related an adjustment service services to XXXX of XXXX. completed the costs XX% As example, XXth been as The of had then the of April the associated allocated prior or will amount in was words, and $X to $X May complete will to April to only will and be already $XXX,XXX. to earnings XX% XXth under value be yet of revenue retained as if proportion period revenue XX% million the XXX equal that a in to million Xst ASC fiscal the fiscal the manufacturing of work completed, recognize other as
the would adoption As to associated April process, fiscal at year result under be between XXXX for a time with increase completed revenue proportion the $X by of for decrease estimate XXX, this standard. by end will the in therefore, programs We prior course the that XXXX accounting million that Avid's also projects not at ongoing decreased not ASC and of $XX forecasted year million. have revenues of of recorded Revenues amount the of XXth. revenue but at been
million range adjustment $X to to is cumulative Additionally, in earnings the retained the of $X million.
XXX certain complications, believe reporting While by the adoption smooth as this time, the will much change ASC our it the financial presents previous we caused of of over eliminates standard. lumpy reporting
it Operations Tracy of my Avid's the call will will to we financial President growth. in us transition this now concludes that such, Bioservices Dan one in I’ll CFO. Hart's Tracy? indicator for priorities As strategy provide of the discuss new a business Avid's This of over leading Avid be as first Kinjerski, turn and Vice believe Business overview. better future, to
